Evidence map›Paper›PMID 30679417›Full record

ArticleBlood cancer journal2019

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Naseema Gangat, Amy Phelps, Terra L Lasho, Christy M Finke, Rangit Vallapureddy, Curtis A Hanson, Rhett P Ketterling, Mrinal M Patnaik, Animesh Pardanani, Ayalew Tefferi

Open access · goldAbstract readLetter
In one paragraph

Article in Blood cancer journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Fedratinib in myelofibrosis.Blood advances · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Naseema GangatDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. gangat.naseema@mayo.edu.
Amy PhelpsDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Terra L LashoDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Christy M FinkeDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Rangit VallapureddyDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Curtis A HansonDivision of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Rhett P KetterlingDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Mrinal M PatnaikDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-6998-662X
Animesh PardananiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Ayalew TefferiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsHumansJanus Kinase 2Molecular Targeted TherapyMutationMyeloproliferative DisordersPrimary MyelofibrosisProtein Kinase InhibitorsThiamineTreatment OutcomeAntineoplastic AgentsJAK2 protein, humanJanus Kinase 2Protein Kinase InhibitorsThiamine

Identifiers

PMID30679417
PMCPMC6345855
OpenAlexW2913951122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.